Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;54(2):160-166.
doi: 10.1111/apt.16410. Epub 2021 Jun 10.

Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study

Antoine Meyer  1   2   3 , Laura Semenzato  1 , Mahmoud Zureik  1   4 , Alain Weill  1 , Franck Carbonnel  2   3 , Rosemary Dray-Spira  1
Affiliations

Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study

Antoine Meyer et al. Aliment Pharmacol Ther. 2021 Jul.

Abstract

Background: Recently, the SECURE-IBD study, based on a physician-reported registry, suggested that thiopurines, either alone or combined with anti-TNF, may increase risk of severe COVID-19.

Aims: To compare the risk of severe COVID-19 according to IBD medications in a large and unselected population.

Methods: Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID-19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio-demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities.

Results: Among 268 185 IBD patients, 600 were hospitalised for COVID-19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID-19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66-1.35) for immunomodulator monotherapy, 1.05 (0.80-1.38) for anti-TNF monotherapy, 0.80 (0.38-1.69) for anti-TNF combination therapy, 1.06 (0.55-2.05) for vedolizumab and 1.25 (0.64-2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID-19 did not differ according to IBD treatment.

Conclusions: Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID-19 infection.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Rubin DT, Abreu MT, Rai V, et al. Management of patients with Crohn's disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology. 2020;159:6-13.e6.
    1. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725-732.
    1. Lees CW, Irving PM, Beaugerie L. COVID-19 and IBD drugs: should we change anything at the moment? Gut. 2021;70:632-634.
    1. Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65:S149-S167.
    1. Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019;50:269-277.

Substances

LinkOut - more resources